Roche obesity drug shows blood sugar control and 15.5% weight loss
Roche said its experimental dual-acting obesity drug improved blood sugar control and drove an average 15.5% body-weight loss in a mid-stage trial in overweight or obese patients with type 2 diabetes.
5% of their body weight in a mid-stage trial. Roche is competing with large drugmakers, including AstraZe…